Prestige Consumer Healthcare (NYSE:PBH) Announces Earnings Results

Prestige Consumer Healthcare (NYSE:PBH) announced its earnings results on Thursday. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04, Zacks reports. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare updated its FY 2025 guidance to 4.500-4.500 EPS.

Prestige Consumer Healthcare Trading Up 14.6 %

NYSE PBH traded up $11.11 during trading hours on Thursday, hitting $87.21. The company’s stock had a trading volume of 768,028 shares, compared to its average volume of 306,855. Prestige Consumer Healthcare has a twelve month low of $60.00 and a twelve month high of $87.39. The firm has a market capitalization of $4.31 billion, a P/E ratio of 21.22, a PEG ratio of 2.15 and a beta of 0.50. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock has a fifty day moving average of $79.13 and a 200 day moving average of $75.26.

Insiders Place Their Bets

In related news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,810 shares of company stock valued at $3,187,300. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on PBH. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reissued a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. Finally, StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.